Cannabinoid treatment for autism: a proof-of-concept randomized trial

BACKGROUND: Endocannabinoid dysfunction in animal models of autism spectrum disorder (ASD) and accumulating, albeit anecdotal, evidence for efficacy in humans motivated this placebo-controlled double-blind comparison of two oral cannabinoid solutions in 150 participants (age 5–21 years) with ASD. ME...

Descripción completa

Detalles Bibliográficos
Autores principales: Aran, Adi, Harel, Moria, Cassuto, Hanoch, Polyansky, Lola, Schnapp, Aviad, Wattad, Nadia, Shmueli, Dorit, Golan, Daphna, Castellanos, F. Xavier
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7860205/
https://www.ncbi.nlm.nih.gov/pubmed/33536055
http://dx.doi.org/10.1186/s13229-021-00420-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7860205/
https://www.ncbi.nlm.nih.gov/pubmed/33536055
http://dx.doi.org/10.1186/s13229-021-00420-2

Ejemplares similares